Table 4.

Associations between polyomavirus seroreactivity and cutaneous SCC stratified by the presence or absence of MCV DNA in the SCC tumor tissues

PolyomavirusControls (n = 300)MCV DNA-positive SCC cases (n = 55)MCV DNA-negative SCC cases (n = 90)MCV DNA-positive versus DNA-negative SCC cases
Seroreactivityn%n%ORa95% CIan%ORa95% CIaORa95% CIa
MCV
 Seronegative8026.7712.71.00Reference2022.21.00Reference1.00Reference
 Seropositive22073.34887.32.491.03–6.047077.81.380.76–2.481.960.76–5.08
 Quartile 17525.0610.91.00Reference1921.11.00Reference1.00Reference
 Quartile 27525.0814.61.830.57–5.912730.01.650.81–3.350.860.25–2.95
 Quartile 37525.01527.32.270.78–6.612932.21.630.81–3.281.620.52–5.04
 Quartile 47525.02647.33.931.43–10.761516.70.800.37–1.765.761.82–18.28
  Ptrend0.010.670.0004
JCV
 Seronegative10836.01425.51.00Reference2730.01.00Reference1.00Reference
 Seropositive19264.04174.61.300.64–2.666370.01.230.72–2.111.240.57–2.69
 Quartile 17525.0814.61.00Reference1718.91.00Reference1.00Reference
 Quartile 27525.01527.32.150.78–5.952224.41.610.76–3.441.600.54–4.77
 Quartile 37525.01120.01.370.48–3.931921.11.090.50–2.341.180.38–3.69
 Quartile 47525.02138.21.450.55–3.813235.61.430.70–2.901.240.44–3.50
  Ptrend0.820.550.93
  • aORs and 95% CIs adjusted for age and sex.